Engineered immune cells take on kidney cancer in first human test
NCT ID NCT07647744
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-phase trial tests a new treatment for advanced kidney cancer that has spread. The therapy uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells. The study will enroll 18 adults and focus on safety and finding the right dose, with a preliminary look at whether the treatment can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
genetically modified immune cells (CAR T-cells) targeting CD70
What this could lead to
If this works, it could point toward a new treatment option for advanced kidney cancer that has stopped responding to other therapies.
What could go wrong
This is a very early Phase 1 trial with only 18 participants, so it is primarily testing safety. The treatment may not shrink tumors or may cause serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA (RCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
RenJi Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, 200000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••